Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > From bad to worse
View:
Post by Momo25 on Sep 18, 2024 3:25pm

From bad to worse

Unreliable company, like TH, deals with unreliable partners that's why news we hear from the board of directors are either bad or worse.
Comment by Trogarzon on Sep 18, 2024 3:36pm
It was in the plan last time it occurred like 10 years ago.  They managed the cost/benefit of having such an insurance and did'nt do it.  From what I recall it was like 5m to requalify a second supplier.  They managed the risk alright, they saved a few millions. Very smart to have put all their money in their still worthless once project.  Looking for new products but ...more  
Comment by Momo25 on Sep 18, 2024 3:49pm
The only product that has some future is now in Jeopardy. usually, when FDA starts putting its nose in something, it's because, generally speaking, it doesn't smell good. Doctors are now aware of the situation, they will be tempted to change their patients prescriptions for something equivalent, which is a bankrupcy pre-announcement. So, when Levesque says he is still on track for 2024, it ...more  
Comment by Trogarzon on Sep 18, 2024 3:54pm
It's the only drug approved for Lypo and it's a problem not linked to Egrifta manufacturing itself.  The plant has issues that they need fixing and I one of the consequence is the FDA approval of new batch.  They might loose a few months of Egrifta sales and that can be a problem.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities